ORIC · ORIC Pharmaceuticals
AI read · Neutral
The AI's read
The cash gives ORIC room to keep developing its drug candidates, and the company said costs rose as that work advanced. It also highlighted progress with rinzimetostat, but gave no trial result or new timing that shows a change in the pipeline's prospects.